Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur

MLA

Christian H, Geisler, et al. “Nordic MCL2 Trial Update: Six-Year Follow-up after Intensive Immunochemotherapy for Untreated Mantle Cell Lymphoma Followed by BEAM or BEAC + Autologous Stem-Cell Support: Still Very Long Survival but Late Relapses Do Occur.” British Journal of Haematology, vol. 158, May 2012, pp. 355–62. EBSCOhost, https://doi.org/10.1111/j.1365-2141.2012.09174.x.

APA

Christian H, G., Arne, K., Anna, L., Mats, J., Riikka, R., Niels S, A., Lone B, P., Mikael, E., Marie, N., Eva, K., Hans, B., Outi, K., Grete F, L., Herman, N.-E., Elisabeth, R., Mats, E., Christer, S., Jan, D., Marja-Liisa, K.-L., … Johan, V. (2012). Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur. British Journal of Haematology, 158, 355–362. https://doi.org/10.1111/j.1365-2141.2012.09174.x

Chicago

Christian H, Geisler, Kolstad Arne, Laurell Anna, Jerkeman Mats, Räty Riikka, Andersen Niels S, Pedersen Lone B, et al. 2012. “Nordic MCL2 Trial Update: Six-Year Follow-up after Intensive Immunochemotherapy for Untreated Mantle Cell Lymphoma Followed by BEAM or BEAC + Autologous Stem-Cell Support: Still Very Long Survival but Late Relapses Do Occur.” British Journal of Haematology 158 (May): 355–62. doi:10.1111/j.1365-2141.2012.09174.x.